Advanced HCC: Patients not eligible for IO - What are the treatment options?

Advanced HCC: Patients not eligible for IO - What are the treatment options?

Prof. Dr James Harding, Medical Oncologist at Memorial Sloan Kettering Cancer Center and Prof. Dr Sammy Saab, Gastroenterologist and Transplant Hepatologist at the David Geffen School of Medicine, both from the USA, discuss the treatment options for advanced hepatocellular carcinoma (HCC) patients who are not eligible for immunotherapy (IO) first line.

In this podcast, the experts give an overview of the current systemic treatment options for patients by looking into the results from different clinical trials and current guidelines, as the field is rapidly evolving since 2017. They discuss the patient cohorts who are not eligible for IO in first line, such as patients with underlying auto-immunity, impaired organ function and patients who decline IO.

The experts discuss the efficacy and safety data from the SHARP and Asia Pacific trials of sorafenib and from the REFLECT trial of lenvatinib, which are both tyrosine kinase inhibitors (TKIs) and available for the aforementioned patient cohorts. They also present their approach to toxicity management for patients receiving those TKIs.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(90)

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer    Key clinical takeaways:   Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multi...

12 Mars 23min

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binar...

17 Dec 202525min

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressi...

7 Nov 202527min

Exploring the role of targeted radiopharmaceutical treatment in NETs

Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing,...

30 Sep 202521min

Tackling mPDAC: chemotherapy strategies that matter

Tackling mPDAC: chemotherapy strategies that matter

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall surv...

19 Maj 202521min

Understanding Rare NSCLC Mutations: Insights, access and support

Understanding Rare NSCLC Mutations: Insights, access and support

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE)...

14 Maj 202520min

The HER2 diagnostic and treatment landscape in NSCLC

The HER2 diagnostic and treatment landscape in NSCLC

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC  This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology B...

28 Apr 202518min

The HER2 Diagnostic and Treatment Landscape in NSCLC

The HER2 Diagnostic and Treatment Landscape in NSCLC

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives  This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC,...

15 Apr 202521min

Populärt inom Utbildning

historiepodden-se
rss-bara-en-till-om-missbruk-medberoende-2
det-skaver
nu-blir-det-historia
harrisons-dramatiska-historia
not-fanny-anymore
roda-vita-rosen
rss-viktmedicinpodden
sektledare
johannes-hansen-podcast
kan-jag-sa-kan-du-podden
i-vantan-pa-katastrofen
allt-du-velat-veta
sa-in-i-sjalen
rikatillsammans-om-privatekonomi-rikedom-i-livet
rss-max-tant-med-max-villman
rss-foraldramotet-bring-lagercrantz
rss-ar-det-rimligt
vi-gar-till-historien
rss-basta-livet